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Abstract
Background: Depression often remains undiagnosed or treated inadequately. Web-based interventions for
depression may improve accessibility of treatment and reduce disease-related costs. This study aimed to examine
the potential of the web-based cognitive behavioral intervention “deprexis” in reducing disease-related costs.
Methods: Participants with mild to moderate depressive symptoms were recruited and randomized to either a 12-
week web-based intervention (deprexis) in addition to care as usual (intervention group) or care as usual (control
group). Outcome measures were health-related resource use, use of medication and incapacity to work as well as
relating direct health care costs. Outcomes were assessed on patients’ self-report at baseline, three months and six months.
Results: A total of 1013 participants were randomized. In both groups total direct health care costs decreased during the
study period, but changes from baseline did not significantly differ between study groups. Numeric differences between
study groups existed in outpatient treatment costs. They could be attributed to differences in changes of costs
for psychotherapeutic treatment from baseline. Whereas costs for psychotherapeutic treatment decreased in the
intervention group, costs increased in the control group (− 16.8% (€80) vs. + 14.7% (€60)) (tdf = 685 = 2.57; p = 0.008).
Conclusion: The study indicates the health economic potential of innovative e-mental-health programs. There is
evidence to suggest that the use of deprexis over a period of 12 weeks leads to a decrease in outpatient treatment
cost, especially in those related to different types of psychotherapeutic treatment.
Keywords: Economic issues, Outcome studies, Health economic evaluation, E-mental-health, Deprexis, Depression,
Randomized controlled trial
Background
Major depression is a worldwide health problem, which
lowers quality of life for the individual and generates
huge costs for society. The lifetime prevalence of a diag-
nosed depression is estimated at 11.6% to 13.0% in Ger-
man adults, with women having a nearly twice as high
risk of disease as compared to men [1–5]. From a
societal perspective, depressive disorders are associated
with a substantial loss of resources. The diagnosis of de-
pression has become the second most important reason
for an incapacity for work [6–8]. In comparison to
people without depression, patients with depressive dis-
order report twice as many days of incapacity for work
[9]. Therefore, employees had an average absence of
51.8 days due to depressive episodes in 2014 [10]. In
addition to indirect costs due to disease related product-
ivity losses, depressive disorders are associated with high
health care costs. Thus, the estimated annual direct
treatment costs for Germany range between €686 and
€3849 per patient within different studies. The total
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direct costs of depression in Germany were estimated at
5,2 billion Euro for the whole population [5, 11].
A depressive episode needs to be treated if symptoms
exceed a certain period, persistence and strength [12].
But despite differentiated guidelines and a well-
developed health care system, depressive episodes are
rarely identified in time and treated adequately. Thus,
many individuals with depression remain untreated, even
in countries with well-developed health care systems
[13]. This globally documented treatment gap in the
management of mental illnesses may be counteracted by
internet based self-help interventions. This form of inter-
vention is particularly relevant as a treatment of mild to
moderate depression [14, 15]. Employed in a stepped-care
model, low intensity online-based interventions may bridge
the treatment gap as an appropriate first option for patients
with mild to moderate depressive symptoms. Advantages
are low threshold, local and temporal independence, reduc-
tions in waiting time for face-to-face treatment, empower-
ment and anonymity [15, 16].
During the recent years different studies along ran-
domized controlled trials as well as some meta-analyses
provided evidence for the clinical effectiveness of e-
mental health interventions (especially in the treatment
of mild to moderate depressive symptoms). For example,
a meta-analysis by Cujipers and colleagues stated that
that self-guided psychological treatment has a small but
statistically significant effect on participants with ele-
vated levels of depressive symptomatology [14]. More-
over, another meta-analysis that was conducted in this
textual context underlined the effectiveness of web-
based interventions in the treatment of depression.
The meta-analysis by Karyotaki et al. demonstrated
self-guided internet-based behavioral therapy to be sig-
nificantly more effective on depressive symptoms sever-
ity and treatment response in comparison to control
conditions [17].
While there is strong evidence for the effectiveness of
web-based treatments for depression, effects on overall
health care costs have been less well researched. In this
context, only a few health economic evaluations exist up
to now, most of them evaluating guided, less commonly
unguided or minimally-guided internet interventions.
Whereas most studies indicated that guided web-based
interventions have the potential to be cost-effective [18],
health economic evaluations of self-guided treatment
programs tend to classify those interventions as not
cost-effective according to direct costs of health services
or productivity losses [19–21].
Against this background, the present study was de-
signed to examine, whether the use of the minimally-
guided cognitive behavioral self-help program deprexis
over a period of 12 weeks in addition to care as usual
leads to a significant reduction in direct health care costs
within six months of observation. The main results of
this study, the EVIDENT-trial, has been published else-
where [22].
Methods
Study design
The EVIDENT-Trial is as a prospective, parallel-group,
multicenter, randomized, controlled and assessor-
blinded study which was conducted between August
2013 and December 2014. The study was approved by
the Ethics Committee of the German Psychological As-
sociation (reference-number SM 04_2012) and registered
at ClinicalTrials.gov (identifier: NCT01636752). A study
protocol with a detailed description of the trial design
has been published [23].
Using an a-priori generated allocation schedule with
random numbers, all participants were randomized into
either an intervention group or a control group. Partici-
pants of the intervention group gained access to the on-
line based self-help program “deprexis” for a period of 12
weeks in addition to care as usual. The program aims to
promote self-management skills as well as to empower
people with depressive symptoms to learn new and health-
ier behaviors. It consists of ten different modules, covering
a broad range of elements of cognitive behavioral therapy
such as behavioral activation and cognitive modification,
psychoeducation, mindfulness and acceptance or interper-
sonal skills. For a detailed description of the program and
all of its modules see Meyer et al. [24].
The control group received care as usual and was per-
mitted to use any kind of therapy or treatment offered
in standard care under the statutory health insurance
scheme (e.g. outpatient medical care, inpatient hospital
care or pharmaceutical care as well as psychiatric or psy-
chotherapeutic treatment). After taking part in the last
follow-up assessment, the participants of the control
group were also invited to use the internet based pro-
gram for a 12-week period.
Participants
Participants were recruited from various settings, includ-
ing inpatient and outpatient medical and psychological
clinics, health insurance companies, online forums for
depression as well as different media (e. g. newspaper
and radio) between August 2012 and December 2013.
Inclusion criteria were the presence of mild to moder-
ate depressive symptoms, defined by scores between 5
and 14 on the Patient Health Questionnaire-9 (PHQ-9),
age between 18 and 65 years, an adequate command of
the German language, the availability of internet access
and electronically written informed consent, which was
obtained online prior to baseline assessment.
People with moderately severe to severe depressive
symptoms (PHQ-9 score > 14), an acute suicidal tendency
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(> 0, PHQ-9 Item 9), a diagnosis of bipolar disorder or
lifetime schizophrenia (both determined by a diagnostic
telephone interview) or other serious mental or physical
illnesses that required acute treatment were excluded
from the study.
Resource use and costing
The health economic evaluation of the EVIDENT-trial
focused on healthcare utilization, medication use and in-
capacity for work due to illness, as well as on resulting
direct costs. Estimates of direct costs were derived from
the payer-perspective. Therefore, patients’ time costs,
traveling costs as well as indirect costs due to absentee-
ism or presentism were not included in the analysis. Fees
for the use of the web based program were excluded
from this analysis, as these are negotiated individually
with clients such as health insurance companies and
vary depending on usage circumstances [25]. Informa-
tion on the amount of the fee for the online intervention
is kept secret for competitive reasons and therefore not
available for the German health care market.
All assessed data were based on participants’ retro-
spective self-reports, collected via an online survey plat-
form at baseline, after three months (post-assessment)
and after six months (follow-up assessment). The recall
periods ranged from six months at baseline to three
months during the post- and the follow-up assessment.
For data collection on healthcare utilization, we used a
modified version of the FIMA [26], a standardized ques-
tionnaire which originally was designed for the assess-
ment of health-related resource use within the older
population groups in cross sectional and longitudinal
surveys. For the purpose of this study, we adapted the
recall-periods of FIMA and extended the list of assessed
medical services by specific psychiatric and psychothera-
peutic treatments. The complete list of assessed medical
services is presented in Table 1.
In order to monetarily value the assessed resource use,
the quantitative data on utilization of services were
priced, using standardized unit costs from Bock et al.
[27]. Costs were calculated by multiplying the units of
resource utilization with corresponding unit cost prices
and are expressed in euro. For further analyses the single
Table 1 Assessed medical services by health care sector and corresponding valuation rates adapted from Bock et al. [28], indexed
for 2014a
Health care sector Unit of measure Service/service provider Valuation rate
Outpatient medical care Number of contacts General practitioner €20.20
Psychiatrist/psychologist €45.03
Psychotherapist/psychotherapy €78.63
Neurologist €45.03
Internist €65.90
Urologist €24.87
Gynaecologist €30.34
Surgeon €43.69
Orthopaedist €25.60
Dermatologist €19.02
Ophtalmologist €35.02
Dentist €56.26
Outpatient paramedical services Number of contacts Physiotherapy €16.53
Logopaedics €38.86
Medical pedicure €27.70
Homeopathic practitioner/osteopath €20.12
Inpatient hospital services Number of days Inpatient hospital treatment €579.93
Inpatient hospital treatment - intensive care unit €1347.08
Psychiatric inpatient treatment €342.09
Rehabilitation Number of days Inpatient rehabilitation €122.70
Outpatient rehabilitation €47.01
Sickness benefit Number of days Incapacity to work €45.01ab
aBock et al. (2015) do not present any unit cost prices for calculating the amount of sickness benefit. The valuation for sickness benefit derives from a large routine-data
analysis of more than 3.000 patients with depressive disorders of a major German sickness fund, conducted by the University of Bielefeld (paper under revision)
blong-term disability more than 60 days
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health care costs were summarized to sector related
health care costs as presented in Table 1.
Following international standards of health economic
evaluation [28], the unit costs from Bock et al. (calcu-
lated for the year 2011) were adjusted for inflation.
Therefore, all cost-rates were adjusted to inflation for
the reference year 2014, based on the German consumer
price sub-index for health care [29].
To calculate the medication costs, we used a large
database (“StammdateiPlus”) with information on all
pharmaceuticals listed in Germany, corresponding active
ingredient groups, defined daily doses, pharmacies’ retail
prices and more. Since the primary data on medication
use were collected between 2012 and 2014, we used the
database version 46 with the latest update in December
2014 [30] for our analyses.
On basis of the StammdateiPlus, we calculated drug-
specific unit costs per pill, injection, suppository etc. first.
Therefore, the pharmacy retail price was used. In a second
step, the number of drug units per recall period was calcu-
lated for each participant, using the assessed self-reports on
dose rate and period of application. Finally, the calculated
units of drug use per recall period were combined with the
drug-specific unit costs to estimate medication costs.
Statistical analysis
Before starting with the data analysis, the whole dataset
was checked for validity. Whenever reported numbers of
resource use (e.g. number of contacts, number of ther-
apy sessions, number of nights spent in hospital)
exceeded the maximum number of days of the corre-
sponding recall period, these single implausible data
were deleted from the dataset and coded as missing.
The basic data analysis focused on descriptive parame-
ters. We used measures of central tendency and mea-
sures of variability to describe differences concerning
the sociodemographic variables or healthcare utilization
between study groups. To determine the precision of
mean values, 95%-confidence intervals were calculated.
Additionally, chi-square tests were utilized for further
examination of observed group differences.
To describe the assessed outcomes in variation of time
and to check the observed values for regularities, time
series analyses were conducted. In cases of normally dis-
tributed data, a paired t-test was carried out. If this con-
dition was not fulfilled, a Wilcoxon signed-rank test was
used. Comparative subgroup-analysis (especially between
IG and CAU) were applied using t-test for independent
samples. In order to check whether the intervention also
has an influence on the costs independently from base-
line costs, we conducted a difference in differences ana-
lysis. Therefore, the difference in costs between baseline
and the study period was calculated. The changes in
mean costs were then examined for differences between
study groups, using paired t-tests for independent sam-
ples. The corresponding h0-hypothesis to be tested was:
there are no significant differences in changes of mean
costs between interventions and controls. Our statistical
analyses are based on all available data (pairwise dele-
tion), as this method has the advantage of using all ob-
served data of each subject and leads to unbiased
estimations. We did therefore not impute missing values
as the used statistical methods are robust and valid for
missing at random data. Besides, complete case analysis
is the most common way of handling missing data in the
analysis of clinical RCTs [31].
To enable a direct comparison of health care expendi-
tures and sickness benefits in variation of time, all costs
were calculated for a six-month period. Therefore, the
health-care expenditures during the post-assessment period
were summed up with those at follow-up assessment. Thus,
the presented cost-analyses refer to the time-periods “six
months pre enrollment” (baseline) versus “six months post
enrolment” (post-assessment and follow-up assessment).
All statistical analyses were performed using IBM SPSS
Statistics for windows version 22.0 and R version 3.3.2.
The calculation of medication costs was conducted with
Microsoft Excel 2016. The final cost variables were reim-
ported to IBM SPSS-statistics for further analyses.
Results
Participant flow
Participants were enrolled in the study between August
2012 and December 2013. Of the 2020 screened subjects,
1007 (49.9%) did not meet the inclusion criteria. Most of
them were excluded because they reached a score on
PHQ-9 of 14 points or more (n = 748; 74.3%). Finally,
1013 participants were randomized into the study groups:
509 to intervention and 504 to care as usual group. The
post-assessment-questionnaire was completed by 781 par-
ticipants (77.1%), 692 (68.3%) completed the 3-months
follow-up questionnaire. There were no significant differ-
ences in rates of attrition at post treatment or 3-months
follow-up between groups. Further, a logistic regression
analysis concluded, that neither randomization group nor
age, sex, family status, educational status, baseline PHQ-
score, baseline diagnosis of depression or panic disorder
were significantly associated with dropout status [22]. To
obtain full information on participant flow, see the CON-
SORT flow chart (Fig. 1).
Participant characteristics
Detailed descriptive statistics for socio-demographic
characteristics are presented in Table 2.
About two-thirds (68.6%) of the 1013 participants who
completed baseline questionnaire were female. The mean
age of the sample was 44 years at baseline, ranging from
18 to 65 years.
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Nearly 60% reported to be married or to have a steady
relationship. Approximately the same number of partici-
pants stated to work on a regular contract (44.0% full-
time, 23.4% part-time). No differences between study
groups were found for any of the sociodemographic vari-
ables (gender: χ2 = 0.011, p = 0.915; age: tdf = 1011 = 0.15,
p = 0.883; material status: χ2 = 6.753; p = 0.240; highest
academic qualification: χ2 = 5.647, p = 0.447, employ-
ment status: χ2 = 2.793, p = 0.940). This indicates that
randomization had been successful.
Health-related resource use
At baseline-assessment, there was no significant differ-
ence in health-related resource use between participants
of the intervention group and those receiving care as
usual, indicating that randomization was well balanced
for resource use as well. Listed medical services or treat-
ments. Briefly, about 80% of the participants in both
groups reported that they took at least one medication
during the past six months, 85% consulted a general
practitioner, about 35% received psychotherapy and
nearly 6% had an inpatient hospital stay.
Table 3 presents the percentage of subjects who re-
ported to have used the listed medical services or treat-
ments. Briefly, about 80% of the participants in both
groups reported that they took at least one medication
during the past six months, 85% consulted a general
practitioner, about 35% received psychotherapy and
nearly 6% had an inpatient hospital stay.
Compared to baseline, the mean percentage of partici-
pants reporting to have received the assessed medical
services six months post enrollment did not differ sig-
nificantly, neither in variation of time nor between study
groups. An exception is treatment by a surgeon or an
orthopedist. Whereas the percentage of participants who
consulted a surgeon or an orthopedist increased by
4.4%age points from 18.9% at baseline to 23.3% six
months post enrollment in the intervention group, it de-
creased by 4.0 percentage points within the care as usual
group (20.6% to 16.6%; between-group difference post-
enrollment: χ2 = 0.011, p = 0.915).
Incapacity for work
In both study groups, the duration of incapacity for
work decreased significantly during the period of six
months post enrollment compared to six months pre en-
rollment (see Fig. 2). The average number of days of in-
capacity to work decreased by 4 days in both groups,
whereas participants of the control-group reported a sig-
nificant higher mean duration of incapacity for work
during the six weeks pre enrollment to the study as well
as during the six months post enrollment (IGpre-post:
19.1 to 15.1 days, − 20.9%, p = 0.001; CAUpre-post: 24.0 to
20.3 days, − 15.4%; p = 0.026). The changes in duration
of incapacity for work did not differ significantly be-
tween groups (tdf = 640 = 0.74; p = 0.462).
Costs
There were no significant differences in total direct
health care costs between the study conditions at base-
line (see Table 4). Six months pre enrolment mean total
direct costs per participant were €2346 in the interven-
tion group and €2475 in the care as usual group, show-
ing only a small difference of €129 (tdf = 980 = 0.35; p =
0.730). During the six months after enrollment in the
trial, mean total costs decreased significantly in both
study groups. In the intervention group, total costs
Fig. 1 CONSORT participant flow chart
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decreased by €631 (tdf = 412 = 1.70; p = 0.002), in the care
as usual group average costs decreased by €625 (tdf =
420 = 4.004; p = 0.000) (see Fig. 3). The average reduction
in total costs did not significantly differ between study
conditions (tdf = 579 = − 1.77; p = 0.139).
Besides, on closer examination of sector-specific health
care costs we found some important differences between
the study groups: Whereas the mean direct costs of out-
patient treatment slightly decreased in the intervention
group, the average per participant costs increased in the
care as usual group (see Table 4). Thus, average out-
patient health care costs decreased by 4.4% (€33) from
€750 to €717 in the intervention group (tdf = 344 = 1.47;
p = 0.144), while costs increased about 11.5% (€78) in
the control group from €684 during the period of six
months before enrollment to €762 six months after en-
rollment to the trial (tdf = 340 = − 1.65; p = 0.099). These
changes in average outpatient costs did significantly dif-
fer between groups (tdf = 684 = 2.16; p = 0.036). The in-
crease in outpatient health care costs in the control
group could mainly be traced back to a rise in costs of
psychotherapeutic treatment: the six months pre enroll-
ment costs for utilization of psychotherapy increased by
€60 on average during the six months post enrollment.
By contrast, mean costs for psychotherapeutic treatment
decreased by €80 in the intervention group. The de-
scribed contrary trend in costs for utilization of psycho-
therapeutic treatment lead to a significant difference in
the development of mean changes between intervention
group and care as usual (tdf = 685 = 2.57; p = 0.008).
Table 2 Sociodemographic characteristics at baseline
Intervention (n = 509) CAU (n = 504) Total (n = 1.013)
n % n % n %
Gender
Male 159 31.2% 159 31.5% 318 31.4%
Female 350 68.8% 345 68.5% 695 68.6%
Age
Mean (SD) 42 (11.1), 42 (10.9) 42 (11.0)
Marital status
Married 203 39.9% 222 44.0% 425 42.0%
Married, but living separated 12 2.4% 16 3.2% 28 2.8%
Single 118 23.2% 129 25.6% 247 24.4%
In relationship 106 20.8% 83 16.5% 189 18.7%
Divorced 65 12.8% 50 9.9% 115 11.4%
Widowed 5 1.0% 4 0.8% 9 0.9%
Highest academic qualificationa
Not yet graduated 2 0.4% 0 0.0% 2 0.2%
No graduation 1 0.2% 0 0.0% 1 0.1%
Lower secondary 29 5.7% 24 4.8% 53 5.2%
Middle secondary 131 25.7% 112 22.2% 243 24.0%
Higher secondary 87 17.1% 85 16.9% 172 17.0%
Highest secondary 249 48.9% 271 53.8% 520 51.3%
Other 10 2.0% 12 2.4% 22 2.2%
Employment statusb
Full time 220 44.4% 214 43.5% 434 44.0%
Regular part-time 117 23.6% 114 23.2% 231 23.4%
Mini-Job 0 0.0% 2 0.4% 2 0.2%
Temporary employed 20 4.0% 25 5.1% 45 4.6%
Retraining 7 1.4% 2 0.4% 9 0.9%
Maternity leave/ parental leave/ other absence 14 2.8% 7 1.4% 21 2.1%
Not working 117 23.6% 128 26.0% 245 24.8%
aHighest academic qualification according to the German classification: “Hauptschule” (“lower”, 9 years, until age 15/16), “Realschule” (“middle”, 10 years, until age
16/17), “Fachhochschulreife” (“higher”, 12 years, until age 17/18), “Abitur” (“highest”, 12 or 13 years, until age 17–19)
bMultiple answers possible
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Table 3 Resource use by health care sector and study condition, six months pre-enrollment versus six months post-enrolment
6 months pre-enrollment 6 months post-enrollment
Intervention
(n = 509)
CAU
(n = 504)
Between-
group
differences
Intervention CAU Between-
group
differences
% n % n χ2 p % n (ntotal) % n (ntotal) χ2 p
Medication 80.7 411 81.3 410 0.060 0.807 81.4 285 (350) 78.1 271 (347) 1.198 0.274
Outpatient medical care General practitioner 85.9 437 85.9 433 0.001 0.979 79.3 279 (352) 82.8 289 (349) 1.434 0.231
Psychiatrist/psychologist 30.1 153 31.5 159 0.263 0.608 34.7 122 (352) 32.7 114 (349) 0.312 0.576
Psychotherapist 36.1 184 33.5 169 0.764 0.382 38.9 137 (352) 42.4 148 (349) 0.883 0.347
Neurologist 14.3 73 17.1 86 1.418 0.234 16.2 57 (352) 18.6 65 (349) 0.721 0.396
Psychiatric day care unit 3.7 19 4.8 24 0.660 0.417 4.3 15 (352) 4.6 16 (349) 0.430 0.835
Internist 17.1 87 15.7 79 0.371 0.542 21.9 77 (352) 16.0 56 (349) 3.873 0.490
Gynecologist/urologist 40.5 206 39.3 198 0.149 0.700 33.8 119 (352) 37.2 130 (349) 0.907 0.341
Surgeon and/or orthopedist 18.9 96 20.6 104 0.503 0.478 23.3 82 (352) 16.6 58 (349) 4.888 0.027
Dermatologist 19.3 98 17.7 89 0.428 0.513 19.3 68 (352) 17.8 62 (349) 0.280 0.597
Ophthalmologist 14.7 75 16.1 81 0.347 0.556 19.3 68 (352) 16.6 58 (349) 0.866 0.352
Dentist 62.1 316 59.5 300 0.696 0.404 54.5 192 (352) 59.3 207 (349) 1.624 0.203
Outpatient hospital treatment 12.6 64 12.9 65 0.240 0.877 8.5 30 (352) 11.7 41 (349) 2.003 0.157
Outpatient paramedical
services
Physiotherapy 31.2 159 29.6 149 0.335 0.562 36.5 126 (345) 27.8 95 (342) 6.018 0.014
Logopedics 0.8 4 0.6 3 1.000a 0.9 3 (345) 0.9 3 (342) 1.000a
Medical pedicure 5.5 28 5.8 29 0.310 0.861 6.1 21 (345) 7.6 26 (342) 0.619 0.431
Homeopathic practitioner/
osteopath
11.8 60 11.3 57 0.570 0.812 14.5 50 (345) 12.9 44 (342) 0.385 0.535
Inpatient hospital treatment Inpatient hospital treatment 7.3 37 10.7 54 3.676 0.055 6.7 23 (345) 6.7 23 (342) 0.001 0.976
Psychiatric inpatient treatment 6.9 35 7.7 39 0.278 0.598 2.0 7 (345) 4.7 16 (342) 3.726 0.540
Rehab Outpatient 0.6 3 1.6 8 2.463 0.292 1.4 5 (345) 1.2 4 (342) 2.154 0.341
Inpatient 6.3 32 6.7 34 5.8 20 (345) 3.5 12 (342)
Sickness benefit 9.5 48 12.2 61 1.947 0.163 7.0 24 (352) 9.5 32 (349) 1.324 0.250
aFisher’s exact test
Fig. 2 Duration of incapacity for work six months pre enrollment compared to six months post enrollment
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In comparison to the described development of out-
patient health care cost, an opposing trend could be iden-
tified when analyzing changes in cost for outpatient
paramedical services. Whereas the mean direct costs for
outpatient paramedical services slightly decreased in the
care as usual group by 6.6% (€6) on average, costs for
utilization of outpatient paramedical services increased in
the intervention group by 31.0% (€24). Even if the change
in costs between baseline and post enrollment was signifi-
cant only for the intervention group (see Table 4), the dif-
ference in development of costs between the study groups
was statistically significant (tdf = 684 = 2.16; p = 0.031). The
significant increase in costs for outpatient paramedical
services in the intervention group was mainly caused by
Table 4 Health care expenditures (in €) by sector and study condition, six months pre-enrollment versus six months post-enrollment
Intervention CAU p-value
between-
group
differences#
Mean 5%
trimmed
mean
95% - CI of the mean p-value
within-group
differences#
Mean 5% trimmed
mean
95% - CI of
the mean
p-value
within-group
differences
Total amount
6 months pre
enrollment
2345.91 1506.42 1842.50 – 2784.98 0.002* 2474.88 1705.61 2032.64 – 2820.61 0.000* 0.730
6 months post
enrolment
1714.91 1681.41 1772.44 – 2525.51 1849.70 1021.75 1231.78 – 1973.36 0.139
Medication costs
6 months pre
enrollment
277.50 33.17 34.25 – 589.26 0.007* 276,96. 45.83 90.82 – 463.09 0.634 0.998
6 months post
enrolment
108.41 26.09 20.09 – 196.74 154.91 19.45 −43.55 – 353.36
Outpatient medical care
6 months pre
enrollment
749.70 585.73 647.40 – 852.0 0.144 683.85 581.25 611.54 – 756.16 0.099 0.302
… thereof
psychotherapy
477.32 313.54 382.85 – 571.8 0.031 405.93 304.76 342.60 – 469.25 0.164 0.218
6 months post
enrolment
716.69 634.68 637.16 – 796.2 762.41 670.20 673.70 – 851.12 0.036*
… thereof
psychotherapy
397.24 325.58 333.67 – 460.8 465.78 370.32 387.18 – 544.39 0.008*
Outpatient paramedical services
6 months pre
enrollment
76.24 53.42 62.10 – 90.37 0.036* 85.66 58.31 69.89 – 101.43 0.411 0.382
6 months post
enrolment
99.90 75.82 81.99 – 117.81 79.99 48.14 59.05 – 100.94 0.031*
Inpatient hospital treatment
6 months pre
enrollment
646.97 61.35 374.47 – 919.48 0.484 680.32 135.49 421.59 – 939.04 0.075 0.862
6 months post
enrolment
374.25 15.63 170.19 – 578.32 468.91 30.01 207.61 – 730.21 0.427
Rehabilitation
6 months pre
enrollment
285.82 39.4 181.9 – 389.8 0.820 297.20 65.61 199.61 – 394.79 0.161 0.875
6 months post
enrolment
275.96 36.3 145.8 – 406.1 188.64 0.00 84.10 – 293.18 0.484
Sickness benefit
6 months pre
enrollment
309.68 78.27 212.65 – 406.70 0.005* 450.89 197.72 328.94 – 572.85 0.000* 0.075
6 months post
enrolment
139.70 24.89 81.30 – 198.10 194.84 65.89 126.21 – 263.47 0.111
#t-test for independent samples; pre enrollment: comparison of mean values, post enrollment: comparison of differences in mean costs between pre and
post enrollment
*p ≤ 0.05
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an increase in utilization of physiotherapeutic treatment.
The average cost per participant decreased about 43.5%
(€27), from €60 six months pre enrollment to €87 at six
months post enrollment.
Costs for inpatient hospital treatment as well as re-
habilitation costs decreased between baseline and six
months post enrollment in both study groups. There
were no significant differences between study conditions,
neither at baseline or post-enrollment nor in mean
changes of costs.
Medication costs also decreased in both groups, but the
reduction in average costs did not significantly differ be-
tween interventions and controls (tdf = 789 = 1.74; p = 0.998).
Discussion
Principal findings
In this study we have not found that the internet inter-
vention has a significant effect on the percentage of
people reporting to have received single healthcare ser-
vices, on incapacity for work due to illness and resulting
total direct costs from payer perspective.
Therefore, the partially perceived changes in sector-
specific health care costs can be traced back to changes
in rates of utilization: decreasing costs as observed in
the field of inpatient treatment, rehabilitation or drug
expenses, result from shortened durations of stay, reduc-
tions in the number of perceived drugs, variations in
dosage or shortened periods of medication use.
Numeric differences in health care expenditures be-
tween study groups existed in outpatient treatment
costs. Whereas the mean direct costs of outpatient treat-
ment slightly decreased in the intervention group (4.4%;
€33), the average per participant costs increased in the
care as usual group (11.5%; €78). The significant differ-
ence in change of outpatient treatment costs could be
attributed to differences in changes of costs for psycho-
therapeutic treatment from baseline. Whereas costs for
psychotherapeutic treatment decreased in the interven-
tion group by 16.8% (€80) during the period of six
months post enrollment to the study, costs increased in
the control group by 14.7% (€60) (see Table 4).
The higher average duration of incapacity for work
which was observed in the intervention group pre and
post enrollment to study cannot be explained by baseline
differences in sociodemographic characteristics, in sever-
ity of depressive symptoms or in the health-related re-
source use. As part of the RCT-design, participants were
randomly assigned to the two study groups. It should
therefore be presumed that the observed higher level of
incapacity for work in the intervention group has a ran-
dom origin. The simultaneous reduction in duration of
incapacity for work in both study groups does not allow
any indication that the use of internet intervention has
led to a significant reduction in absenteeism.
Previous studies
Our estimated total direct health care costs are higher
than average direct health care costs of other previously
performed economic evaluations. To the best of our
knowledge, for the German context only two studies
exist, which give a detailed description for total direct
per patient costs of depression. Whereas the estimated
annual direct treatment costs in these studies differ be-
tween €686 [[32] and €3849 [33] per patient, the esti-
mated total cost for a period of only six months differs
between about €2350 to €2500 at baseline and €17001 to
€1850 six months post assessment within our study (see
Table 1). It has to be noted, that the methodology of cost
assessment and cost calculation in both studies differed
from our approach. The first study focused on average
Fig. 3 Total health care expenditure six months pre versus six months post enrollment
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direct health care costs of non-institutionalized adults
with depression. In contrast to our study, rehabilitation
costs, outpatient paramedical services and sickness bene-
fit were not taken into account, which could be an ex-
planation for the significantly lower estimated average
costs. Furthermore, because of the restriction to the
non-institutionalized population costs might be underes-
timated [32]. The second study assessed service
utilization (including inpatient, outpatient and rehabili-
tative services) and total direct costs of care in patients
with depressive disorder. Again, outpatient paramedical
services and sickness benefit were not included in the
cost calculation. Additionally, the assessment of medica-
tion costs was limited to the depression-specific treat-
ment, prescriptions due to somatic illness were not
taken into account [33].
A further difference between our study and previously
published studies regards to the instruments used to as-
sess the health-related resource utilization. A recently
published meta-analysis on cost-effectiveness of internet-
based interventions for the treatment of depression [18]
provides an overview of the cost assessment instruments
that were used within twelve trials focusing on the cost-
effectiveness of e-mental-health interventions. Half of the
studies used the “Trimbos and Institute of Medical Tech-
nology Assessment Cost Questionnaire for Psychiatry”
(TiC-P) to assess direct medical and non-medical costs
[18]. The TiC-P allows for the measurement of medical
costs as well as productivity losses in patients with a men-
tal disorder. In contrast to the FIMA the TiC-P only fo-
cusses on the assessment of contacts within the mental
healthcare sector and the use of medication [34]. The
FIMA-questionnaire, on the other hand, covers total costs
of care.
Several studies have documented that (acute) psychi-
atric disorders are associated with an increased use of
primary care resources but also with a more frequent
use of outpatient specialist care [9, 35]. Against this
background, the FIMA-questionnaire provides more
comprehensive information on healthcare utilization.
This could be another reason for the higher estimated
costs values within our study.
In conjunction with further differences in cost
categorization approaches or differences within the study
sample the illustrated differences in survey methods and
used instruments limit the comparability of this trial
with previously published studies.
A strength of our study is the large sample size. In
comparison to other published studies in this research
area our study benefits from the huge number of partici-
pants enrolled in the trial. To the best of our knowledge
the present health economic evaluation is the first pub-
lished one, which was conducted alongside a prospective
randomized controlled trial with a sample size of more
than 1000 participants [18]. Another advantage is the wide
range of recruitment settings, varying from outpatient to
inpatient settings as well as from specialized web-based
communication platforms for people with depressive dis-
orders to media used by the general population. The wide
range of recruitments settings contributes the extern val-
idity of the present research and supports the hypothesis,
that the intervention is effective across different recruit-
ment sources including clinical settings, which could be
demonstrated by Klein et al. in another analysis in the
context of the EVIDENT-trial [36].
One aspect less focused within this manuscript is the
clinical efficacy of deprexis. However, since the medical
benefits are of great importance in the context of health
economic evaluations, it should be noted that different
studies along randomized controlled trials as well as a
meta-analysis provided evidence for the clinical effect-
iveness of deprexis. Thus, a comparison from eight stud-
ies demonstrated the effectiveness of deprexis for
depressive symptoms at post-intervention, with a
medium effect size of g = 0.54 (95% CI: 0.39–0.69) [25].
The results of the EVIDENT-trial also confirm the clin-
ical effectiveness of the program. The study was able to
demonstrate that internet intervention was superior to
CAU alone in reducing mild to moderate depressive
symptoms [22].
Limitations
Some limitations should be considered when interpret-
ing the results of our study. First, our health economic
evaluation was conducted alongside a large multicenter
study which was primarily designed to test clinical ef-
fectiveness of the internet intervention deprexis. There-
fore, the EVIDENT-trial was powered to detect a post-
treatment group difference in depression on the main
outcome variable PHQ-9 [23]. Possible savings due the
use of deprexis were not taken in account when calculat-
ing the sample-size. This could be a potential reason for
the rather small and mostly not significant differences in
direct costs between study groups. Furthermore, the
relatively short follow-up period of six months could be
another reason for only little differences in health care
utilization, medication use, absenteeism due to sickness
and resulting costs. Thus, further research is needed to
assess the long-term health economic effects (at least
two or three years of follow up) of e-mental-health inter-
ventions like deprexis.
All collected data were based on patients’ self-reports.
Even though we used a standardized instrument for the
evaluation of participants’ resource utilization, the
assessed health related resource use may suffer from
under-reporting due to memory failure or over-reporting
due to recall bias. For the purpose of this study, the re-
call time frames of the FIMA (seven days for medication
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use, three months for outpatient medical care and out-
patient paramedical services and 12months for inpatient
hospital treatment and rehabilitation) had to be stan-
dardized and adjusted to the general follow-up dates of
the multicentre trial (six months at baseline and three
months at post-treatment and follow-up). The relatively
long recall periods, especially the period of six months
at baseline, may strengthen these effects. As recent stud-
ies revealed, the reliability of collected data is clearly re-
stricted by the degree to which patients accurately recall
quantities of resources used [34, 37, 38]. Hence, different
methods have been suggested to prevent reporting-bias
or to correct assessed primary data for recall bias. The
most common ways suggested for solving these prob-
lems are using patient controls as well as blinding the
participants for the study hypothesis being tested [39],
which both was realised in the present study.
Another limitation exists with regard to the transfer-
ability of the study results. Firstly, study enrollment was
limited to people aged between 18 and 65 years as well
as to those with mild to moderate depressive symptoms.
Therefore, the results cannot be generalized to older
people or patients with severe depression. In comparison
to the corresponding German general population, partic-
ipants in the EVIDENT-trial had a higher educational
level and women were overrepresented in the study
(68.6% females vs. 31.4 percent males) [40–42]. As Späth
et al. demonstrated, these findings are in line with previ-
ous studies [42]. Thus, the higher proportion of women
can be explained by a twice as high prevalence of
moderate depression among women compared to
men. Furthermore, women seem to be more likely to
seek help then men, as a cross-sectional study on pat-
terns of lay and professional help-seeking in men and
women showed [42, 43]. The higher educational level
within this trial could be explained by a higher de-
mand for internet interventions in people with a
higher educational level, which was shown for users
of a web-based computer-tailored intervention pro-
moting heart-healthy behaviours [44].
One further limitation is that the interventions costs
could not be included to the analysis, as this economic
evaluation was derived from payer perspective and nego-
tiated license-fees for health insurance companies are
not published. The only publicly available price-
information relates to a single license for private persons
(use of deprexis over a period of 90 days) which amounts
to €297.50 including value-added tax [45]. Providing
framework contracts with health insurance companies,
the program-fees from payer perspective can be assumed
to be significantly lower than those for individuals. As
shown in Table 4, there is a statistically not significant
difference of €135 in mean total costs at six months
post-enrollment. It is possible that this difference in total
costs could be offset if the program costs are taken into
account.
A last limitation that should be noticed is that the
conducted costing methodology is only able to generate
approximatively information on direct health care costs.
The utilization of unit costs for the monetarily valuation
of health-related resource use cannot express actual per
participant costs. To give an example: costs for inpatient
hospital treatment were calculated by multiplying the
number of days spent at hospital with a unit cost rate
per day, whereas reimbursement within the German in-
patient hospital sector is based on fees per case. Further-
more, the reimbursement-system in the outpatient
sector combines elements of capitation payment with
those of fee for service payments. However, costing by
unit costs is a common and approved methodological
approach for calculating health care costs within health
economic evaluation studies [37, 46].
Conclusion
The present study indicates the health economic poten-
tial of innovative e-mental-health programs. Our results
suggest that the simultaneous use of web-based self-
help programs for depression in combination with
care as usual leads to a significant decrease in out-
patient treatment costs, especially in those related to
different types of psychotherapeutic treatment. With
regard to the strong evidence for the clinical effect-
iveness of deprexis [22], we would recommend the
use of this program when weighing up cost and bene-
fits. Although no significant savings in total health
care costs could be demonstrated, from a health eco-
nomic perspective the gained clinical benefits are a
strong argument for the use of the cognitive behav-
ioral self-help program.
Considering the above-mentioned limitations of our
study, further research on health economic effects of
innovative internet programs in the treatment of de-
pressive disorders seems necessary to verify our find-
ings by addressing remaining methodical limitations
as well as to widen evidence for (positive) health eco-
nomic effects such as savings in direct and indirect
health care cost.
Endnotes
1Total amount of direct health care costs in the inter-
vention group without costs of the intervention (value
therefore differs from that shown in Table 1).
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